## Projected health and economic effects of nonavalent versus bivalent human papillomavirus vaccination in preadolescence in the Netherlands

## SUPPLEMENTARY MATERIAL

Birgit Sollie, Johannes Berkhof, Johannes A. Bogaards

Amsterdam UMC, Dept. Epidemiology & Data Science, Amsterdam, The Netherlands

July 17, 2024

## Contents

1	Supplementary Annex A: Methods							
	1.1	Bayesian posterior simulation	2					
	1.2	HPV genotype attributions	3					
	1.3	From infection risk to cancer incidence reductions	4					
		1.3.1 Setting	4					
		1.3.2 Estimation of gamma parameters	4					
		1.3.3 Estimated durations to cancer diagnosis	6					
		1.3.4 Probability of HPV infection age given cancer diagnosis	7					
		1.3.5 Number of cancers prevented	8					
	1.4	Anogenital warts episodes	8					
		1.4.1 Incidence	8					
		1.4.2 Treatment costs	9					
	1.5	Recurrent respiratory papillomatosis	10					
		1.5.1 Incidence	10					
		1.5.2 Patient costs	10					
	1.6	.6 Cancer screening and treatment costs						
		1.6.1 CIN2/3 patient costs $\ldots$	11					
	1.7	Utilities for non-lethal conditions	12					
<b>2</b>	Sup	oplementary Annex B: Results	13					
	2.1	Sensitivity analysis	13					
3	Sup	oplementary Annex C: Reporting standards	22					
4	$\mathbf{Ref}$	erences	<b>24</b>					

## **1** Supplementary Annex A: Methods

In this section of the supplementary material, we provide detailed information about the different parts of our data-driven analysis. Some subsections deal with the computational framework used, while others relate to data and input parameters. The entire analysis was performed in R (64bit 4.2.1) and the code is available via github (BirgitSollie/HPV-COMPARE).

#### **1.1** Bayesian posterior simulation

A recurring theme in our data-driven analysis involves the use of Bayesian analysis to translate uncertainty about the data into credible intervals for the outcomes. Instead of using fixed parameter estimates, we sampled the parameters from posterior distributions derived from the data.

Our analysis concerns the estimation of expected numbers of events in a cohort of girls and boys invited for HPV vaccination. These numbers were computed according to life-table methodology, based on transitions between health states and to death. The parameters describing these transitions were estimated from population-level data. For practical purposes, all data that we used was divided into age groups and instead of rates we estimated event probabilities, i.e. the probability of the event to occur for an individual in a particular age group. For instance, we computed the probability of a cervical cancer diagnosis in age group [40, 45) conditional on having survived to age 40. The posterior distribution for this parameter was obtained as follows.

Let  $X_i$  be a random variable equal to the total number of events in the *i*-th age group with  $x_i$  equal to its corresponding observation. Let  $n_i$  be equal to the total number of individuals at risk in this age group. We assume  $n_i$  to be fixed. Let  $\theta_i$  be equal to the event probability, and assume a Beta(0.5, 0.5) prior on  $\theta_i$ . Under the assumption that events between individuals are independent,  $X_i$  follows a binomial distribution with parameters  $n_i$  and  $\theta_i$ . We then see that

$$\mathbb{P}(\theta_i|x_i) \propto \theta^{-0.5} (1-\theta)^{-0.5} \theta^{x_i} (1-\theta)^{n_i - x_i}$$
$$= \theta^{x_i - 0.5} (1-\theta)^{n_i - x_i - 0.5},$$

which means that the posterior distribution of  $\theta_i$  follows a Beta $(x_i + 0.5, n_i - x_i + 0.5)$  distribution.

The number of events of interest in the simulated cohort was subsequently obtained by randomly drawing from the posterior distributions for age-specific transition probabilities, with background mortality considered as a competing event. It is noted that we ignored mortality from other HPVrelated cancers as competing events. This approximation greatly facilitates the computation, and is acceptable because the type- and site-specific cancer risks are small. The expected loss in life-years  $L_k(a_0)$  due to HPV-related cancers (k = f for females and k = m for males) aged  $a_0$  years was calculated as the sum over all HPV-associated tumour sites j (cervical, anal, oropharyngeal, vulvar and vaginal cancer in case k = f; oropharyngeal, anal and penile cancer in case k = m), as follows:

$$L_k(a_0) = \sum_j p_{k,j} \sum_{a \ge a_0} g_{k,j}(a;a_0) \, l_{k,j}(a) \, da.$$

Here,  $p_{k,j}$  denotes the tumour- and possibly sex-specific probability that a cancer is caused by HPV,  $g_{k,j}(a;a_0)$  represents the sex-specific population-averaged risk of having cancer j diagnosed in age group a conditional on having survived until age  $a_0$ , and  $l_{k,j}(a)$  is the sex-specific number of life-years lost if HPV-associated cancer j is diagnosed in age-group a. We refer to the supplementary information of our previous publications for further elaboration on the computation of loss in (quality-adjusted) life years from HPV-related cancers [1,2].

For estimation of event rates in the absence of HPV vaccination, we performed B = 1000 random draws for all parameters and performed cohort simulations by selecting the *b*-th draw for each parameter of interest. This resulted in *B* different outcomes for each particular number of events, with the mean and variance reflecting the expectation and the uncertainty in the data, respectively.

When projecting the effects of HPV vaccination, we made use of the same random draws, augmented by B random draws for disease-specific HPV genotype attribution (see subsection 1.2), typespecific infection risk reductions obtained from the HPV transmission model [3], and time from HPV infection to cancer diagnosis (see subsection 1.4). Differences between vaccination scenarios were calculated for each b-th draw of all parameters and summarized afterward. Thus, the differences between bivalent and nonavalent HPV vaccination are estimated conditional on uncertainty in the data.

#### 1.2 HPV genotype attributions

The HPV genotype attributions in CIN2/3 were estimated specifically for this study from large Dutch population-based trial data [4,5], using a previously developed maximum likelihood method that adjusts for multiple infections within subjects [6]. The attributions in cancer were obtained from the literature [7-12]. Table 1 gives an overview of the genotype attributions that we used as input for our analysis.

	16	18	31	33	39	45	51	52	58
Screening									
CIN2/3, age 30	0.5628	0.0619	0.1144	0.0691	0.0101	0.0274	0.0364	0.0402	0.0360
CIN2/3, age 35+	0.4698	0.0807	0.1317	0.0665	0.0253	0.0233	0.0482	0.0569	0.0427
Cancer									
Cervix	0.6550	0.0729	0.0335	0.0569	0.0131	0.0389	0.0136	0.0194	0.0131
Anus	0.8082	0.0365	0.0183	0.0274	0.0046	0.0091	0.0000	0.0068	0.0183
Oropharynx	0.8819	0.0176	0.0032	0.0235	0.0016	0.0037	0.0000	0.0016	0.0059
Vulva	0.7283	0.0468	0.0094	0.0656	0.0070	0.0328	0.0000	0.0187	0.0094
Vagina	0.5875	0.0495	0.0528	0.0495	0.0198	0.0363	0.0231	0.0297	0.0363
Penis	0.6877	0.0150	0.0090	0.0300	0.0060	0.0270	0.0090	0.0150	0.0120

Table 1: Genotype attribution in CIN2/3 and cancer

In line with subsection 1.1, we sampled the genotype attributions from posterior distributions of which the mean values are equal to the values in Table 1. In this case, however, the parameter is a vector,  $\theta = (\theta_{16}, \theta_{18}, \theta_{31}, \theta_{33}, \theta_{39}, \theta_{45}, \theta_{51}, \theta_{52}, \theta_{58}, \theta_{other})$ , where  $\theta_j$  defines the fraction of CIN2/3 lesions (or cancers) in the population caused by HPV genotype j and  $\sum_j \theta_j = 1$ . Let  $X = (X_{16}, X_{18}, X_{31}, X_{33}, X_{39}, X_{45}, X_{51}, X_{52}, X_{58}, X_{other})$ , where  $X_j$  is equal to the number of cases in the data caused by HPV type j. Let  $x = (x_{16}, \ldots, x_{other})$  be the corresponding vector of observations, and  $n = \sum_j x_j$  equal to the total number of cases. We assume n to be fixed and assume a Dirichlet $(0.5, \ldots, 0.5)$  prior on  $\theta$ . Under the assumption that all individuals are independent, X follows a multinomial distribution with parameters n and  $\theta$ . Using a similar reasoning as above, it can be shown that the posterior distribution of  $\theta$  then follows a Dirichlet $(x + (0.5, \ldots, 0.5))$  distribution.

#### **1.3** From infection risk to cancer incidence reductions

The time between HPV infection and the development of invasive cancer is usually long, possibly decades. Therefore, in the presence of waning efficacy, the probability that an observed cancer case can be prevented by vaccination depends on the the age distribution of HPV acquisition. Stated differently, we need a way to translate the age-specific reduction in HPV infection risk, obtained from the HPV transmission model, into reduction in the incidence of HPV-related cancers. In this subsection, we discuss step by step how we achieved this. First, we estimated the time between HPV infection and cancer diagnosis based on the age distributions in the incidence of HPV infection and cancer diagnosis based on the age distributions in the incidence of the age of infection given a cancer diagnosis in a particular age group. Third, we projected the reduction in cancer diagnoses by age group based on the age-specific risk reductions for HPV infection.

#### 1.3.1 Setting

Given development of cancer caused by HPV, the age of diagnosis can be modelled as follows. Let  $T_1$  be the age of HPV infection and  $T_2$  the time of that HPV infection to the cancer diagnosis (given that the infection will develop into cancer). Hence  $T_{ca} = T_1 + T_2$  is equal to the age of cancer diagnosis caused by HPV. We assume  $T_1$  and  $T_2$  to be independent. Note that  $T_{ca}$  is only observed when the individual is still alive at time  $T_{ca}$ .

In the following, we assume that the HPV incidence by age is known from the HPV transmission model (see subsection 1.3). The distribution of  $T_1$  then follows from this HPV incidence by conditioning on acquiring HPV somewhere during life. We discretize time in years resulting in a discrete probability distribution on the sample space  $\{1, 2, ..., 100\}$  with corresponding probabilities  $p_1, p_2, ..., p_{100}$  where  $\sum_{a=1}^{100} p_a = 1$ . We further assume that  $T_2$  follows a gamma distribution on  $(0, \infty)$  with unknown parameters  $k, \theta > 0$  and density function

$$f_{T_2}(t) = \Gamma^{-1}(k)\theta^{-k}t^{k-1}e^{-t/\theta}.$$

In the next subsection we show how the parameters k and  $\theta$  can be estimated from the distribution of  $T_1$  and cancer incidence data. A key component is that given the distributions of  $T_1$  and  $T_2$ , the distribution of  $T_{ca} = T_1 + T_2$  follows from the convolution of the distribution of  $T_1$  and the density of  $T_2$ ;

$$f_{T_{ca}}(t) = \sum_{a} p_a f_{T_2}(t-a)$$

#### 1.3.2 Estimation of gamma parameters

Our goal is to estimate the gamma parameters k and  $\theta$  in the density of  $T_2$  from the distribution of  $T_1$ and cancer incidence data. Suppose we have data on the actual number of cancer diagnoses between age  $b_1$  and  $b_{\ell+1}$ , subdivided in  $\ell$  different age groups. We define these age groups as  $[b_1, b_2)$ ,  $[b_2, b_3)$ , ...,  $[b_{\ell}, b_{\ell+1})$ . We introduce random variables  $X_1, \ldots, X_{\ell}$ , where  $X_i$  is equal to the number of actual cancer diagnoses in the *i*-th age group. Observed values of  $X_1, \ldots, X_{\ell}$  are denoted by  $x_1, \ldots, x_{\ell}$ . We can estimate k and  $\theta$  by likelihood maximization. The likelihood function can be written as

$$\mathcal{L}(k,\theta|X_1=x_1,\ldots,X_\ell=x_\ell)=\mathbb{P}_{k,\theta}(X_1=x_1,\ldots,X_\ell=x_\ell).$$

Given that a cancer is diagnosed,  $(X_1, \ldots, X_\ell)$  follows a multinomial distribution with probabilities  $q_1, \ldots, q_\ell$ , where  $q_i = \mathbb{P}(b_i \leq T_{ca} < b_{i+1}|T_{ca} < T_d)$  with  $T_{ca}$  equal to the age of cancer diagnosis as defined in the previous subsection and  $T_d$  equal to the age of death (by other causes). We assume that  $T_{ca}$  and  $T_d$  are independent. Then

$$\mathbb{P}_{k,\theta}(X_1 = x_1, \dots, X_{\ell} = x_{\ell}) = \frac{\sum_{i=1}^{\ell} x_i}{x_1!, \dots, x_{\ell}!} q_1^{x_1} \cdots q_{\ell}^{x_{\ell}}$$

hence

$$\log \mathcal{L}(k,\theta|X_1 = x_1, \dots, X_\ell = x_\ell) \propto \sum_{i=1}^\ell x_i \log q_i.$$
(1)

Note that  $q_i$  depends on the unknown parameters k and  $\theta$ , and

$$q_i = \frac{\mathbb{P}(b_i \le T_{ca} < b_{i+1}, T_{ca} < T_d)}{\mathbb{P}(T_{ca} < T_d)}.$$

We have

$$\mathbb{P}(T_{ca} < T_d) = \int_0^\infty f_{T_{ca}}(t) \, s_t \, dt$$

where  $s_t$  is equal to the survival probability  $\mathbb{P}(T_d > t)$ . Similarly, we have

$$\mathbb{P}(b_i \le T_{ca} < b_{i+1}, T_{ca} < T_d) = \int_{b_i}^{b_{i+1}} f_{T_{ca}}(t) \, s_t \, dt.$$

Hence,

$$q_{i} = \frac{\int_{b_{i}}^{b_{i+1}} f_{T_{ca}}(t) s_{t} dt}{\int_{0}^{\infty} f_{T_{ca}}(t) s_{t} dt}.$$
(2)

We assume that there are no cancer diagnoses before age  $b_1$  and after age  $b_{\ell+1}$ , so that  $\sum q_i = 1$ . To evaluate the integrals in (2), we set  $s_t = 0$  for  $t \ge b_{\ell+1}$ . In the previous subsection we have seen how the density of  $T_{ca}$  follows from the convolution of  $T_1$  and  $T_2$ . Hence,

$$\int_{b_i}^{b_{i+1}} f_{T_{ca}}(t) s_t dt = \int_{b_i}^{b_{i+1}} \sum_a p_a f_{T_2}(t-a) s_t dt$$
$$= \sum_a p_a \int_{b_i}^{b_{i+1}} f_{T_2}(t-a) s_t dt.$$

The survival probabilities are assumed to be available with steps of one year, hence we can write

$$\int_{b_i}^{b_{i+1}} f_{T_2}(t-a) s_t dt = \sum_{k=1}^{b_{i+1}-b_i} s_{b_i+k-1} \int_{b_i+k-1}^{b_i+k} f_{T_2}(t-a) dt$$
$$= \sum_{k=1}^{b_{i+1}-b_i} s_{b_i+k-1} \int_{b_i+k-1-a}^{b_i+k-a} f_{T_2}(t) dt$$
$$= \sum_{k=1}^{b_{i+1}-b_i} s_{b_i+k-1} (F_{T_2}(b_i+k-a) - F_{T_2}(b_i+k-1-a)).$$

It follows that

$$\int_{b_i}^{b_{i+1}} f_{T_{ca}}(t) s_t dt = \sum_a p_a \sum_{k=1}^{b_{i+1}-b_i} s_{b_i+k-1} (F_{T_2}(b_i+k-a) - F_{T_2}(b_i+k-1-a))$$

and similarly

$$\int_{0}^{\infty} f_{T_{ca}}(t) s_{t} dt = \int_{b_{1}}^{b_{\ell+1}} f_{T_{ca}}(t) s_{t} dt$$
$$= \sum_{a} p_{a} \sum_{k=1}^{b_{\ell+1}-b_{1}} s_{b_{1}+k-1} (F_{T_{2}}(b_{1}+k-a) - F_{T_{2}}(b_{1}+k-1-a))$$

Therefore,

$$q_{i} = \frac{\sum_{a} p_{a} \sum_{k=1}^{b_{i+1}-b_{i}} s_{b_{i}+k-1} (F_{T_{2}}(b_{i}+k-a) - F_{T_{2}}(b_{i}+k-1-a))}{\sum_{a} p_{a} \sum_{k=1}^{b_{\ell+1}-b_{1}} s_{b_{1}+k-1} (F_{T_{2}}(b_{1}+k-a) - F_{T_{2}}(b_{1}+k-1-a))}.$$

Using the above expression for  $q_i$ , the right-hand side of (1) can be maximized numerically (e.g. using the optim() function in R), which gives the maximum likelihood estimates for k and  $\theta$ .

#### **1.3.3** Estimated durations to cancer diagnosis

Here, we present pooled estimates of the time from overall high-risk HPV infection incidence to diagnosis of various types of cancer, using cancer incidence data collected from the Netherlands Cancer Registry for the years 2015-2019. This cancer data is given in 15 age groups of width 5 between age 15 and 90 ( $b_1 = 15, b_2 = 20, \ldots, b_\ell = 85, b_{\ell+1} = 90$ ). To approximate the overall high-risk HPV infection incidence from type-specific incidences, we combined the type-specific estimates obtained from the HPV transmission model [3] (in a setting without HPV vaccination) with HPV genotype data from two large Dutch population-based screening trials [4,5]. In these trials, genotyping was assessed for HPV-positive women at baseline for 14 (possibly) high-risk HPV genotypes. We approximated the overall high-risk HPV incidence by a weighted sum of the type-specific HPV incidences, where the weights are based on the proportion of genotypes found in the data. We used a hierachical classification method. We first ranked the genotypes from most prevalent to least prevalent, resulting in the following ranking; 16, 31, 18, 52, 51, 56, 45, 33, 58, 66, 39, 35, 59, 68. Each genotype was then weighted by the fraction of women positive for that genotype and negative for all genotypes that were more prevalent in the data (ranked higher). We assumed the weights to be the same for men and women.

Figure 1 displays the age distributions of a general HPV infection and diagnosis of various types of cancer used as input for the estimation. Table 2 shows the estimated gamma parameters and the corresponding mean duration from overall high-risk HPV infection incidence to cancer diagnosis. Note that cervical cancer is diagnosed at much younger age then the other cancers, which is also reflected in the mean duration in Table 2.

#### Age distributions HPV and cancer



Figure 1: The age distributions for a general HPV infection (black) and cancer, for women in panel A and men in panel B.

Cancer type	k	$\theta$	mean duration $(k \cdot \theta)$
Cervix	5.39	3.62	19.54
Anus (w)	20.91	1.91	39.97
Anus (m)	13.09	2.92	38.26
Oropharynx (w)	24.78	1.58	39.18
Oropharynx (m)	25.73	1.47	37.82
Vulva	8.19	5.00	40.97
Vagina	10.33	3.90	40.33
Penis	22.27	1.96	43.56

#### Table 2: Estimated gamma parameters

#### 1.3.4 Probability of HPV infection age given cancer diagnosis

Our next goal is to compute the conditional probability

$$\mathbb{P}(T_1 = a \,|\, b_i \le T_{ca} < b_{i+1}, T_{ca} < T_d),$$

that is, the probability that an individual was infected with HPV at age a given that cancer (caused by this infection) was diagnosed in the age interval  $[b_i, b_{i+1})$ . We will need this probability later to compute risk reductions in cancer. By the definition of a conditional probability we have

$$\mathbb{P}(T_1 = a \mid b_i \le T < b_{i+1}, T_{ca} < T_d) = \frac{\mathbb{P}(T_1 = a, b_i \le T < b_{i+1}, T_{ca} < T_d)}{\mathbb{P}(b_i \le T < b_{i+1}, T_{ca} < T_d)}.$$
(3)

Remember that  $T_{ca} = T_1 + T_2$  and  $T_1, T_2$  and  $T_d$  are independent, hence for the numerator we have

$$\mathbb{P}(T_1 = a, b_i \le T < b_{i+1}, T_{ca} < T_d) = p_a \int_{b_i - a}^{b_{i+1} - a} f_{T_2}(t) s_{t+a} dt$$
$$= p_a \int_{b_i}^{b_{i+1}} f_{T_2}(t-a) s_t dt$$

The denominator follows from the formula of the numerator by summing over all values of  $T_1$ :

$$\mathbb{P}(b_i \le T < b_{i+1}, T_{ca} < T_d) = \sum_a \mathbb{P}(T_1 = a, b_i \le T < b_{i+1}, T_{ca} < T_d)$$
$$= \sum_a p_a \int_{b_i}^{b_{i+1}} f_{T_2}(t-a) s_t dt.$$

Combining the expressions for the numerator and the denominator in (3), we obtain

$$\mathbb{P}(T_1 = a | b_i \le T < b_{i+1}, T_{ca} < T_d) = \frac{p_a \int_{b_i}^{b_{i+1}} f_{T_2}(t-a) s_t dt}{\sum_a p_a \int_{b_i}^{b_{i+1}} f_{T_2}(t-a) s_t dt}$$

#### 1.3.5 Number of cancers prevented

In this last part we use the conditional probability  $\mathbb{P}(T_1 = a \mid b_i \leq T < b_{i+1}, T_{ca} < T_d)$  to compute the risk reduction on cancer. From this point on we need to distinguish between the different HPV types, since the vaccines only protect against a subset of HPV genotypes. We assume that the distribution of  $T_1$  and  $T_2$  is the same for all types.

Let  $RRR_a^j$  be the relative risk reduction on HPV infection with type j at age a corresponding to a chosen vaccination strategy. The risk reductions are estimated by the HPV transmission model and include both direct vaccine effects and indirect herd effects. Then for each age group  $[b_i, b_{i+1})$  of cancer diagnosis caused by HPV type j, we compute the relative reduction in cancer incidence as

$$RRR_{b_i, b_{i+1}}^{ca, j} = \sum_{a} \mathbb{P}(T_1 = a \mid b_i \le T < b_{i+1}, T_{ca} < T_d) RRR_a^j.$$

To obtain the number of cancers prevented for this age group and HPV type j, we multiply  $RRR_{b_i,b_{i+1}}^{ca,j}$  with the number of cancers expected for that age group and HPV genotype in the absence of HPV vaccination.

#### 1.4 Anogenital warts episodes

#### 1.4.1 Incidence

Population-level data on anogenital warts (AGW) episodes in the Netherlands was available from general practices, aggregated into very broad age groups [13], see Table 3. It is noted that the incidence rate of AGW is slightly underestimated, because some episodes are diagnosed in sexual health centers, which we did not take into account. However, about 95% of all AGW diagnoses in the Netherlands are made by the GP [13], so the bias is small.

Table 3: Anogenital warts episodes per 1000 individuals in 2020

	< 25	$\geq 25$
Women	2.7	2.1
Men	2.1	3.5

To obtain fine-grained age trends in AGW episodes from age 25 onward, we used reported trends in the number of sexual partners by 15-year age groups, for both men and women [14,15]. Finegrained trends in AGW episodes below age 25 were obtained from a recent GP registry study, that used a representative sample of about 10% of the Dutch population to estimate the incidence of AGW diagnoses in primary care by age among adolescent girls and young women aged 12-22 years [16]. These rates were re-scaled, with linear interpolation for age 22 to 25, to match the populationaveraged incidence rate among women below age 25. For males, we assumed the same age trend as for females aged 12-22 years, and re-scaled results to also match the population-averaged incidence rate among young men below age 25. The resulting estimate of AGW episodes by age is shown in Figure 2.





Figure 2: Estimated AGW incidence per 1000 person years (p-yrs) for women (red) and men (blue).

#### 1.4.2 Treatment costs

The costs per treatment episode for anogenital warts were obtained from an epidemiological analysis on the economic burden of genital warts in Dutch primary care [17]. This study used data from the Nivel primary care database over the years 2011-2021. The total costs of treating warts in Dutch primary care increased from EUR 2.3 million in 2011 to EUR 4.9 million in 2021. The costs per case including referrals to secondary care increased from EUR 93.3 in 2015 to EUR 117.4 in 2021. After extrapolation and indexation to 2023, we arrived at treatment costs of EUR 128.7 per anogenital warts episode for use in this analysis.

#### 1.5 Recurrent respiratory papillomatosis

#### 1.5.1 Incidence

We used international publications to obtain the age-specific incidence of recurrent respiratory papillomatosis (RRP). We assumed a prevalence of  $1/200\,000$  person-years for juvenile onset RRP and a prevalence of  $1/500\,000$  person-years for adult onset RRP [18]. For each patient we assumed an exponentially distributed duration with a mean of 10 years. The age distribution of RRP onset was assumed to follow a mixture of three log-normal distributions [19] and is displayed in Figure 3.



Figure 3: Age distribution of RRP onset

#### 1.5.2 Patient costs

RRP patient costs were calculated per patient per year, using a microcosting approach based on unpublished data from the two academic medical centers in Amsterdam in calendar years 2018 and 2019, with 84 and 97 patients treated in either year, respectively [20]. Taken together, approximately 25% of all RRP patients in the Netherlands are seen in either of these two hospitals.

The direct costs included outpatient visit costs, day care and hospitalization costs, diagnostic costs (including laryngology, morphology of biopsy samples, ultrasound, blood tests), and therapeutic laryngology costs. Unit direct costs were based on tariffs used in the two hospitals in 2018 and 2019. The indirect costs included production loss costs and travel costs to the academic medical center. Production loss costs per hour and travel costs per kilometer were taken from [21]. Distance to the hospital was calculated from zip codes of the patient's home address and the hospital. Travel costs comprised 10% and 13% of the indirect costs in years 2018 and 2019, respectively. The production loss costs were adjusted for labor participation percentages, stratified by age and sex, as reported by Statistics Netherlands. Production loss costs also included costs of assisting children with RRP to the hospital.

Average direct and indirect costs per patient per year, weighted by the number of patients in the

two hospitals, are presented in Table 4. Summing the average direct and indirect costs yielded a total of EUR 2579 per RRP patient per year.

Direct costs	$\mathrm{Cost}~(\textcircled{\bullet})$	Indirect costs	$\mathrm{Cost}~(\textcircled{\bullet})$
Outpatient consult visit	249.30	Production loss	510.30
Diagnostics	246.40	Travel costs	51.70
Treatment (laryngoscopy)	1044.10		
Daycare/ hospitalization	313.70		
Other (e.g. speech therapy)	118.10		

Table 4: Costs per RRP patient per year

All costs were indexed to the year 2023.

#### 1.6 Cancer screening and treatment costs

Costs of cancer screening and treatment are presented in Table 1 of the main article. Costs of cancer treatment are based on a previous publication [22], and updated to 2023 using the consumer price index. Costs of screening, including colposcopy referral following a positive HPV-test and non-normal cytology, were based on the subsidy regulation to the cervical cancer screening program determined by the Dutch government. The costs of follow-up and treatment of CIN2/3 is elaborated below.

#### 1.6.1 CIN2/3 patient costs

The costs per CIN2/3 diagnosis were calculated from the nationwide network and registry of histo- and cytopathology [23] and a population-based screening trial database [24]. The CIN2/3 costs included the number of indicative screening tests after colposcopy referral but before diagnosis, the number of follow-up screening tests after treatment (either cytology or HPV-testing), and the number of colposcopy-guided biopsies. We assumed that all CIN3 cases and a 65% of CIN2 cases were eventually treated and that treatment of residual CIN2/3 was needed in 15% of the cases [23,25,26]. Unit costs for the indicative and follow-up screening tests were taken from [27], unit LLETZ treatment costs were taken from [28], and costs per outpatient clinic visit were taken from [21]. The number of procedures per patient and costs per CIN2 and CIN3 diagnosis are presented in Table 5.

	Cost category	No.	Cost per procedure $({\mathfrak C})$	Cost per diagnosis $({\mathfrak C})$	Source
CIN2					
	Colposcopies	4.56	191.70 (first)	757	[21, 25]
			158.80 (repeat)		
	Biopsies	2.01	70.10	141	[21, 25]
	LLETZ	0.75	701.00	526	$[19-21,\!23,\!25]$
	Co-tests after treatment	2.55	60.60	155	[21, 25]
Total				1578	
CIN3					
	Colposcopies	4.89	191.70 (first)	809	[21, 25]
			158.80 (repeat)		
	Biopsies	2.30	70.10	161	[21, 25]
	LLETZ	1.15	701.00	806	$[19-21,\!23,\!25]$
	Co-tests after treatment	2.59	60.60	157	[21, 25]
Total				1934	

### Table 5: Direct costs per CIN2/3 diagnosis

All costs were indexed to the year 2023.

## 1.7 Utilities for non-lethal conditions

In sensitivity analyses, we also expressed the incremental cost-effectiveness ratio (ICER) of 9vHPV versus 2vHPV vaccination in terms of the cost per quality-adjusted life-years (QALYs) gained. This acknowledges that 9vHPV confers additional health benefits by not only reducing the incidence of HPV-related cancers relative to 2vHPV vaccination, but also by reducing the occurrence of non-lethal conditions. To this end, we attributed a loss in quality of life to precancerous lesions, anogenital warts and RRP. For precancerous lesions, we assumed a QALY loss of 0.035 per CIN2/3 detected [29]. For anogenital warts, we attributed a QALY loss of 0.018 for each treatment episode [30]. For RRP, we assumed a QALY loss of 0.105 per patient per year [31].

## 2 Supplementary Annex B: Results

In this section of the supplementary material we provide more numerical and graphical results.

## 2.1 Sensitivity analysis

# Table 6: Quantiles of ICERs of 9vHPV versus 2vHPV vaccination for different scenarios corresponding to the one-way and two-way sensitivity analyses

Scenario	$Q_{0.025}$	$Q_{0.25}$	$Q_{0.5}$	$Q_{0.75}$	$Q_{0.975}$
One-way					
Base-case	6192	4166	5588	6758	7916
No LR types	17173	14719	16389	18060	19866
LR elimination	4120	1941	3494	4701	5824
No cross-protection	-1566	-2259	-1776	-1348	-973
High cross-protection	12882	9300	11776	14081	16589
Very high cross-protection	22558	16040	20181	25037	32709
QALYs instead of LYs	2009	1412	1821	2201	2514
HPV vaccine uptake $50\%$	4114	2409	3600	4634	5697
HPV vaccine uptake $70\%$	12888	10438	11954	13758	15631
Price difference EUR 35	-1830	-3484	-2346	-1321	-534
Price difference EUR 70	16839	13949	16004	17810	19922
Waning	59499	48995	56057	63788	72315
International discounting	11297	7614	10209	12362	14565
Two-way					
Very high cross-protection $+$ LR elimination	18163	12267	16060	20490	27120
High cross-protection $+$ no LR types	31297	25846	29259	33089	37435
QALYs instead of LYs + very high cross-protection	4322	3485	4030	4598	5125
HPV vaccine uptake $50\%$ + very high cross-protection	15801	11046	14075	17853	22452
HPV vaccine uptake $70\%$ + no LR types	25438	21785	24010	26756	29551
HPV vaccine uptake $70\%$ + high cross-protection	31069	24322	28514	33913	41720
Price difference EUR $35 + \text{very high cross-protection}$	5750	1919	4507	7163	10044
Price difference EUR $70 + no LR$ types	27944	24041	26637	29225	32369
Price difference EUR $70 + high cross-protection$	30740	24828	28658	32811	37457
Price difference EUR 70 + HPV vaccine uptake $70\%$	27116	23127	25550	28674	31826
Waning + LR elimination	53364	43446	50086	57417	65058
Waning $+$ no cross-protection	22563	18927	21185	23951	26772
Waning + QALYs instead of LYs	8974	7810	8573	9336	9941
Waning + HPV vaccine uptake $50\%$	49614	40581	46610	53105	60611
Waning + Price difference EUR 35	36103	28667	33513	38725	44547



Cost-effectiveness profile 9vHPV- vs 2vHPV vaccination

Figure 4: ICERs of 9vHPV versus 2vHPV vaccination for different scenarios in the two-way sensitivity analysis. The light-grey vertical line corresponds to an ICER equal to zero. The cost-effectiveness threshold of C20,000 per (quality-adjusted) life-year gained is displayed by the dashed vertical line. Boxplots display median and interquartile range of predictions, with whiskers denoting the 95% credible intervals

The plots below show the cost-effectiveness planes for the comparison of 9vHPV- versus 2vHPV vaccination for various assumptions also considered in the sensitivity analysis. Each plot shows nine scenarios regarding cross-protection (cp) and evaluated impact on the low-risk HPV types.

Cost-effectiveness plane 9vHPV vs 2vHPV vaccine Effect of cross-protection (cp) and the LR HPV genotypes



Figure 5: Cost-effectiveness plane 9vHPV- vs 2vHPV vaccination. The cost-effectiveness threshold of  $\textcircled{C}20\ 000$  per LY gained is shown by the orange line.

Cost-effectiveness plane 9vHPV vs 2vHPV vaccine Waning efficacy



Figure 6: Cost-effectiveness plane 9vHPV- vs 2vHPV vaccination under waning vaccine efficacy. The cost-effectiveness threshold of  $\textcircled{C}20\ 000$  per LY gained is shown by the orange line.

Cost-effectiveness plane 9vHPV vs 2vHPV vaccine QALYs instead of life-years



Figure 7: Cost-effectiveness plane 9vHPV- vs 2vHPV vaccination using QALYs gained instead of life-years only. The cost-effectiveness threshold of  $\pounds$ 20,000 per life-year gained (LYG) is shown by the orange line.

Cost-effectiveness plane  $9\nu HPV$  vs  $2\nu HPV$  vaccine Vaccine uptake 50%



Figure 8: Cost-effectiveness plane 9vHPV- vs 2vHPV vaccination when the vaccine uptake is equal to 50% for both boys and girls. The cost-effectiveness threshold of C20,000 per LYG is shown by the orange line.

Cost-effectiveness plane  $9\nu HPV$  vs  $2\nu HPV$  vaccine Vaccine uptake 70%



Figure 9: Cost-effectiveness plane 9vHPV- vs 2vHPV vaccination when the vaccine uptake is equal to 70% for both boys and girls. The cost-effectiveness threshold of C20,000 per LYG is shown by the orange line.

Cost-effectiveness plane 9vHPV vs 2vHPV vaccine Price difference (9vHPV-2vHPV): €35



Figure 10: Cost-effectiveness plane 9vHPV- vs 2vHPV vaccination when the price difference (9v-2v) is EUR 35. The cost-effectiveness threshold of  $\leq 20,000$  per LYG is shown by the orange line.

Cost-effectiveness plane 9vHPV vs 2vHPV vaccine Price difference (9vHPV-2vHPV): €70



Figure 11: Cost-effectiveness plane 9vHPV- vs 2vHPV vaccination when the price difference (9v-2v) is EUR 70. The cost-effectiveness threshold of  $\leq 20,000$  per LYG is shown by the orange line.

Cost-effectiveness plane 9vHPV vs 2vHPV vaccine International discounting (3%, 3%) with CE threshold €50 000 / LY gained



Figure 12: Cost-effectiveness plane 9vHPV- vs 2vHPV vaccination under international discounting of 3%, 3%. The cost-effectiveness threshold of  $€50\ 000$  per LY gained is shown by the orange line.

## 3 Supplementary Annex C: Reporting standards

HPV-FRAME is a CONSORT-style itemised checklist encapsulating agreed reporting standards that has been structured according to 7 domains reflecting distinct policy questions in HPV and cancer prevention. Its goal is to support understanding regarding a model's strength and weaknesses and contribute to equitable, evidence-based decision-making. This investigation adheres to the quality framework for modelled evaluations of HPV-related cancer control through prophylactic vaccination in preadolescence (domain no. 1), for which the core set plus 10 additional reporting standards apply [32]. These are summarized in Table 7.

a) Inputs	Report by age	Report by sex	Comments
Target population for intervention	Υ	Υ	Vaccination of girls $+$ boys
			in the Netherlands at age $10$
Sexual behaviour	Y (implicitly)	Y (implicitly)	Rates and mixing patterns in
			original publication (3)
Time horizon	Υ	Υ	Lifetime cohort evaluation at
			post-vaccination equilibrium
Quality of life assumptions	Υ	Υ	Part of sensitivity analysis
Calibration	N/A	N/A	Data-driven analysis,
			does not rely on calibration
Validation	N/A	N/A	No targets available
	V	V	C C
Costs	Y	Y	See Supplementary Annex A
Vaccine uptake	Y	Y	Varied in sensitivity analysis.
	-	-	assumed equal by sex
Vaccine efficacy	Y	Y	Efficacy informed by $CIN2/3$ .
			assumed equal for other diseases
Vaccine cross-protection	Y	Y	Cross-protection for 2v vaccine,
Ĩ			assumed equal by sex
Duration vaccine protection & waning	Y	Y	Varied in sensitivity analysis,
			assumed equal by sex
Vaccine delivery and costs	Y	Y	Total costs per 2-dose schedule,
U U			assumed equal by sex
Pre-vaccination disease burden	Y	Y	HPV attributions independent
(incl. attributable fractions for HPV)			of age, except for $CIN2/3$
Duration of natural immunity	Υ	Y	Exponential waning rates,
			assumed equal by sex
b) Outputs	Reported	Report by sex	Comments
Absolute reductions in HPV or warts	Y	Ν	Reductions in anogenital warts
			and RRP for 9v vaccine
Absolute reductions in $CIN2/3$	Y	N/A	Reduction in $CIN2/3$ given for
			direct and total effects
Absolute reductions in invasive cancer	Y	Υ	Reductions in cancers given
			for direct and total effects

## Table 7: HPV-FRAME reporting standards for vaccination in adolescents

## 4 References

- Bogaards JA, Wallinga J, Brakenhoff RH, Meijer CJ, Berkhof J. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ. 2015; 350:h2016.
- Qendri V, Bogaards JA, Baussano I, Lazzarato F, Vänskä S, Berkhof J. The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment. Lancet Public Health. 2020; 5(11):e592-e603.
- Bogaards JA, Xiridou M, Coupé VMH, Meijer CJLM, Wallinga J, Berkhof J. Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus. Am J Epidemiol. 2010; 171(7):817-25.
- 4. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer. 2004; 110(1):94-101.
- Rijkaart DC, Berkhof J, van Kemenade FJ, Rozendaal L, Verheijen RH, Bulk S, et al. Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in population-based cervical screening (VUSA-screen study). Int J Cancer. 2010; 126(9):2175-81.
- Lissenberg-Witte BI, Bogaards JA, Quint WGV, Berkhof J. Estimating the human papillomavirus genotype attribution in screen-detected high-grade cervical lesions. Epidemiology. 2019; 30(4):590-6.
- 7. Alemany L, Cubilla A, Halec G, Kasamatsu E, Quiros B, Masferrer E, et al. Role of human papillomavirus in penile carcinomas worldwide. Eur Urol. 2016; 69(5):953-61.
- Alemany L, Saunier M, Alvarado-Cabrero I, Quiros B, Salmeron J, Shin HR, et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2015; 136(1):98-107.
- Alemany L, Saunier M, Tinoco L, Quiros B, Alvarado-Cabrero I, Alejo M, et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer. 2014; 50(16):2846-54.
- de Sanjose S, Alemany L, Ordi J, Tous S, Alejo M, Bigby SM, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer. 2013; 49(16):3450-61.
- de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11):1048-56.

- Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsague X, Laporte L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and metaanalysis. Lancet Oncol. 2014; 15(12):1319-31.
- 13. van Wees DA, Visser M, van Aar F, Op de Coul ELM, Staritsky LE, Sarink D, et al. Sexually transmitted infections in the Netherlands in 2021. RIVM; 2022.
- 14. Wijsen C, de Haas S. Seksuele gezondheid in Nederland 2011 [in Dutch]. Tijdschrift voor Seksuelogie. 2012; 36(2):83-86.
- Anonymous. Kerncijfers Leefstijlmonitor seksuele gezondheid 2019 [in Dutch]. Rutgers/Soa Aids Nederland; 2021.
- 16. Woestenberg PJ, Guevara Morel AE, Bogaards JA, Hooiveld M, Schurink-van 't Klooster TM, Hoebe C, et al. Partial protective effect of bivalent human papillomavirus 16/18 vaccination against anogenital warts in a large cohort of Dutch primary care patients. Clin Infect Dis. 2021; 73(2):291-7.
- 17. Veijer C, Bes J, Dolk C, Postma MJ, de Jong LA. Epidemiological trends and economic burden of genital warts in Dutch primary care. medRxiv 2024; 2024.06.03.24307801.
- Pogoda L, Ziylan F, Smeeing DPJ, Dikkers FG, Rinkel R. Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review. Eur Arch Otorhinolaryngol. 2022; 279(9):4229-40.
- San Giorgi MR, van den Heuvel ER, Tjon Pian Gi RE, Brunings JW, Chirila M, Friedrich G, et al. Age of onset of recurrent respiratory papillomatosis: a distribution analysis. Clin Otolaryngol. 2016; 41(5):448-53.
- 20. Gielgens T, Kliffen T, Berkhof J, Dikkers FG. Annual and direct costs of recurrent respiratory papillomavirus in the Netherlands. Amsterdam UMC; unpublished report.
- Anonymous. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg [in Dutch]. Zorginstituut Nederland; 2016.
- 22. de Kok IM HJ, van Rosmalen J, van Ballegooijen M. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness? Eur J Cancer. 2011; 47(3):428-35.
- 23. Anonymous. Verbetersignalement Baarmoederhalsafwijking CIN [in Dutch]. Zinnige Zorg; 2019.
- 24. Polman NJ, Ebisch RMF, Heideman DAM, Melchers WJG, Bekkers RLM, Molijn AC, et al. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Lancet Oncol. 2019; 20(2):229-238.
- 25. Kremer WW, Dick S, Heideman DAM, Steenbergen RDM, Bleeker MCG, Verhoeve HR, et al. Clinical regression of high-grade cervical intraepithelial neoplasia is associated With absence of

FAM19A4/miR124-2 DNA methylation (CONCERVE Study). J Clin Oncol. 2022; 40(26):3037-46.

- 26. Kocken M, Helmerhorst TJ, Berkhof J, Louwers JA, Nobbenhuis MA, Bais AG, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol. 2011; 12(5):441-50.
- 27. Jansen E, Naber SK, Aitken CA, de Koning HJ, van Ballegooijen M, de Kok I. Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study. BJOG. 2021; 128(3):573-82.
- 28. van Ballegooijen M, Rebolj M, Essink-Bot ML, Meerding WJ, Berkers LM, Habbema JDF. De effecten en kosten van het bevolkingsonderzoek naar baarmoederhalskanker in Nederland na de herstructurering [in Dutch]. Erasmus MC, Rotterdam; 2006.
- Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim JJ. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia. Vaccine. 2013; 31(Suppl 7):H71-9.
- Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ. 2011; 343:d5775.
- Chesson HW, Forhan SE, Gottlieb SL, Markowitz LE. The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine. 2008; 26(35):4513-8.
- 32. Canfell K, Kim JJ, Kulasingam S, Berkhof J, Barnabas R, Bogaards JA, et al. HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control. Papillomavirus Res. 2019; 8:100184.